T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations

PLoS One. 2011 Feb 18;6(2):e17185. doi: 10.1371/journal.pone.0017185.

Abstract

Background: The extreme genetic diversity of the human immunodeficiency virus type 1 (HIV-1) poses a daunting challenge to the generation of an effective AIDS vaccine. In Argentina, the epidemic is characterized by the high prevalence of infections caused by subtype B and BF variants. The aim of this study was to characterize in mice the immunogenic and antigenic properties of the Env protein from CRF12_BF in comparison with clade B, employing prime-boost schemes with the combination of recombinant DNA and vaccinia virus (VV) vectors.

Methodology/principal findings: As determined by ELISPOT from splenocytes of animals immunized with either EnvBF or EnvB antigens, the majority of the cellular responses to Env were found to be clade-specific. A detailed peptide mapping of the responses reveal that when there is cross-reactivity, there are no amino acid changes in the peptide sequence or were minimal and located at the peptide ends. In those cases, analysis of T cell polifunctionality and affinity indicated no differences with respect to the cellular responses found against the original homologous sequence. Significantly, application of a mixed immunization combining both clades (B and BF) induced a broader cellular response, in which the majority of the peptides targeted after the single clade vaccinations generated a positive response. In this group we could also find significant cellular and humoral responses against the whole gp120 protein from subtype B.

Conclusions/significance: This work has characterized for the first time the immunogenic peptides of certain EnvBF regions, involved in T cell responses. It provides evidence that to improve immune responses to HIV there is a need to combine Env antigens from different clades, highlighting the convenience of the inclusion of BF antigens in future vaccines for geographic regions where these HIV variants circulate.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / therapeutic use
  • Amino Acid Sequence
  • Animals
  • BALB 3T3 Cells
  • Cells, Cultured
  • Female
  • HIV Antigens / genetics
  • HIV Antigens / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV-1 / classification*
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • HeLa Cells
  • Humans
  • Immunity, Cellular / immunology*
  • Immunization / methods*
  • Mice
  • Mice, Inbred BALB C
  • Models, Biological
  • Molecular Sequence Data
  • T-Cell Antigen Receptor Specificity / immunology*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / physiology
  • env Gene Products, Human Immunodeficiency Virus / chemistry
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • HIV Antigens
  • env Gene Products, Human Immunodeficiency Virus